Verma Rita P, Dasnadi Shaeequa, Zhao Yuan, Chen Hegang H
Division of Neonatology, Department of Pediatrics, Nassau University Medical CenterEast MeadowNew York.
Section of Neonatology, Department of Pediatrics, Houston Methodist Sugarland NurseriesHoustonTexas.
Proc (Bayl Univ Med Cent). 2019 May 3;32(3):355-360. doi: 10.1080/08998280.2019.1585732. eCollection 2019 Jul.
Early postnatal hypotension in premature infants is treated with escalating doses of vasopressor-inotropes (VI), followed by hydrocortisone if VI therapy fails. The adverse effects of this standard clinical practice have not been well reported. In a retrospective case-control study, we compared the complications associated with VI and hydrocortisone (HCVI) treatments in extremely low-birth-weight infants (≤1000 g) with contemporaneous normotensive medication-naïve controls via standard univariate and multivariate analyses. Birth weight, gestational age, and receipt of antenatal steroids did not differ between VI ( = 74) and control ( = 124) groups, while the occurrence of gestational diabetes mellitus and risks for patent ductus arteriosus, intraventricular-periventricular hemorrhage, spontaneous intestinal perforation, ventriculomegaly, and bronchopulmonary dsyplasia were higher in VI. Infants in the HCVI group ( = 69) had lower birth weight, gestational age, and receipt of antenatal steroids and higher risks for intraventricular-periventricular hemorrhage, bronchopulmonary dysplasia, air leaks, and patent ductus arteriosus than controls. Whereas the occurrences of spontaneous intestinal perforation, ventriculomegaly, and maternal diabetes mellitus did not differ, that of maternal hypertension trended to be lower in HCVI recipients ( = 0.06). In conclusion, hypotensive extremely low-birth-weight infants treated with VI or with HCVI are susceptible to intraventricular-periventricular hemorrhage, bronchopulmonary dysplasia, and patent ductus arteriosus. Furthermore, those who receive inotropes are at risk for spontaneous intestinal perforation and ventriculomegaly. Maternal diabetes mellitus increases the occurrence of hypotension, which responds to VI. Maternal hypertension does not contribute to VI responsive and tends to decrease the occurrence of VI-refractory hypotension.
早产婴儿出生后早期低血压的治疗方法是逐步增加血管升压药 - 正性肌力药(VI)的剂量,如果VI治疗失败则使用氢化可的松。这种标准临床实践的不良反应尚未得到充分报道。在一项回顾性病例对照研究中,我们通过标准单变量和多变量分析,比较了极低出生体重儿(≤1000 g)接受VI和氢化可的松联合VI(HCVI)治疗与同期血压正常且未接受过药物治疗的对照婴儿的并发症情况。VI组(n = 74)和对照组(n = 124)之间的出生体重、胎龄和产前类固醇的使用情况没有差异,但VI组中妊娠期糖尿病的发生率以及动脉导管未闭、脑室内 - 脑室周围出血、自发性肠穿孔、脑室扩大和支气管肺发育不良的风险更高。HCVI组(n = 69)的婴儿出生体重、胎龄和产前类固醇的使用情况低于对照组,脑室内 - 脑室周围出血、支气管肺发育不良、气漏和动脉导管未闭的风险高于对照组。虽然自发性肠穿孔、脑室扩大和母亲糖尿病的发生率没有差异,但HCVI治疗组母亲高血压的发生率有降低趋势(P = 0.06)。总之,接受VI或HCVI治疗的低血压极低出生体重儿易患脑室内 - 脑室周围出血、支气管肺发育不良和动脉导管未闭。此外,接受正性肌力药治疗的婴儿有自发性肠穿孔和脑室扩大的风险。母亲糖尿病会增加低血压的发生率,且对VI有反应。母亲高血压与VI反应无关,且倾向于降低VI难治性低血压的发生率。